The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree budesonide orodispersible tablets for inducing remission in patients with eosinophilic oesophagitis in line with NICE TA708.
Budesonide orodispersible tablet for this indication will be considered as RED on the traffic light status (treatment should be initiated by gastroenterology teams).

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effected and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.